Yōni.Fit received 510(k) clearance from the US Food and Drug Administration (FDA) in August 2024 following completion of a national clinical trial by Urogynecologists at Stanford, NYU, and Jefferson Health.
“Too many companies fail because they do not take the steps necessary to protect their IP. Others are forced to spend exorbitant amounts of money to fix IP problems that could have been avoided and that, in the end, can never be fully fixed. Watkins-Conti on the other hand, is poised to succeed.”
Jennie Martel – Chief of Global Brand Protection, Colgate-Palmolive
